课题基金 / 基金详情

Cord Blood Graft Engineering to Improve Engraftment and Reduce GVHD

Cord Blood Graft Engineering to Improve Engraftment and Reduce GVHD
脐带血移植工程可改善移植并减少 GVHD
批准号:
10247041
负责人:
Elizabeth J Shpall
金额:
$53.2万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-22 至 2023-08-31

项目摘要

项目成果

Elizabeth J Shpall的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结 脐带血移植(CBT)比骨髓移植有明显的优势 外周血干细胞,但其更广泛的使用一直受到干细胞和 CB单位中的祖细胞,导致植入延迟和植入率很高 失败了。在过去的PO1资助期间,我们开发了一种骨髓来源的间充质基质 细胞(MSC)-CB共培养系统,使我们能够显著加快中性粒细胞和 血小板植入术。这一进展与结果显示的体外细胞表面是平行的 利用岩藻糖基转移酶(FT)-6酶与GDP-岩藻糖结合,可促进CB的岩藻糖基化 通过促进脐带血归巢到骨髓进行植入。因此,在项目1中,我们现在提出一个经修订的 针对我们的长期目标的一系列研究:使CBT的结果与结果保持一致 报道了G-CSF动员的外周血祖细胞(目标1和2)。这一努力将 基于CB细胞的MSC扩增和胞外糖基化的组合来测试CBT FT-7是第二种岩藻糖基转移酶,比FT-6更具生理性,甚至可能更高 能有效促进骨髓植入。 此外,移植物抗宿主病(GVHD)继续限制CBT的应用,这是我们 在过去的PO1颁奖期间没有具体谈到。CBT术后III~IV级移植物抗宿主病发生率 从5%到30%不等。在我们的患者中,那些患有急性肝脏和胃肠道(GI)移植物抗宿主病的患者 显著受益于MSC治疗。在异种GVHD模型中,我们观察到 岩藻糖基化的骨髓间充质干细胞可以增强对炎症部位的归巢,从而获得惊人的存活率 与未经处理的MSC治疗结果进行比较。我们最近也有 观察到,脐带血组织来源的间充质干细胞在后勤上更容易获得和扩增更多 比骨髓来源的骨髓间充质干细胞快。因此,我们现在建议测试CB组织来源的, 岩藻糖基化的MSCs可用于根除急性、激素耐药的肝脏和/或GI GVHD(目标3)。 这个项目的互动潜力是相当大的,例如,目标1的临床试验将 可能会刺激与项目2(重建病毒特异性CTL)、项目3(NK)的合作 项目4(恢复肿瘤特异性免疫)。最后,我们要强调, 项目1的许多发现不会局限于CBT,而是可以扩展到更远的地方 移植到GVHD和再生医学等不同环境的时间。
英文摘要
PROJECT SUMMARY Cord blood transplantation (CBT) has clear advantages over transplantation with bone marrow or peripheral blood stem cells, but its wider use has been limited by the low dose of stem and progenitor cells in CB units, leading to delays in engraftment and a substantial rate of engraftment failure. During the past PO1 funding period, we developed a marrow-derived mesenchymal stromal cell (MSC)-CB coculture system that allowed us to significantly accelerate the time to neutrophil and platelet engraftment. This advance was paralleled by results showing that ex vivo cell-surface fucosylation of CB, using the fucosyltransferase (FT)-6 enzyme with GDP-fucose can boost engraftment by promoting CB homing to marrow. Thus, in Project 1, we now propose a revised series of studies directed to our long-term goal: bringing the results of CBT in line with outcomes being reported for G-CSF-mobilized peripheral blood progenitor cells (Aims 1 and 2). This effort will test CBT based on the combination of MSC-expansion of CB cells followed by exofucosylation with FT-7 a second fucosyltransferase that is more physiologic than FT-6 and could be even more effective at enhancing engraftment in the marrow. Additionally, graft-versus-host disease (GVHD) continues to restrict the utility of CBT, an issue we did not address specifically during the past PO1 award. Rates of grade III-IV GVHD after CBT range from 5% to 30%. In our patients, those with acute liver and gastrointestinal (GI) GVHD have significantly benefited from MSC treatment. In a xenogenic GVHD model, we have observed that fucosylated MSCs can enhance homing to sites of inflammation, resulting in a striking survival benefit compared with the outcome of unmanipulated MSC treatment. We have also recently observed that CB tissue-derived MSCs are logistically easier to obtain and expand much more rapidly than marrow-derived MSCs. Thus we now propose to test whether CB tissue-derived, fucosylated MSCs can be used to abrogate acute, steroid-refractory liver and/or GI GVHD (Aim 3). The interactive potential of this project is considerable, for example, the clinical trial in Aim 1 will likely stimulate collaborations with Project 2 (reconstitution of virus-specific CTLs), Project 3 (NK cell recovery) and Project 4 (recovery of tumor-specific immunity). Finally, we would stress that many of the findings from Project 1 will not be restricted to CBT, but could extend well beyond times to engraftment to settings as diverse as GVHD and regenerative medicine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
Cord Blood Graft Engineering to Improve Engraftment and Reduce GVHD
Cord Blood Expansion and Homing to Improve Engraftment
Administrative Core
海外基金